Amphetamine/Dextroamphetamine IR Shortage: What Providers and Prescribers Need to Know in 2026

Provider briefing: The stimulant shortage enters its fourth year

The amphetamine mixed salts (generic Adderall IR) shortage, which began in October 2022, continues to impact patients and prescribers heading into 2026. While the supply picture has improved compared to the crisis-level scarcity of 2023, clinicians are still fielding calls from patients who cannot fill their prescriptions.

This article provides an evidence-based overview of the current shortage status, its systemic causes, and practical guidance for managing your prescribing workflow during continued supply constraints.

Timeline of the shortage

Understanding how we got here helps contextualize current decision-making:

• October 2022: The FDA officially lists amphetamine mixed salts as in shortage after Teva Pharmaceutical Industries — the largest generic manufacturer — reports manufacturing and supply delays.
• 2023: The shortage peaks. Multiple generic manufacturers report demand exceeding supply. Patients report going weeks without medication. FDA Drug Shortage Database lists multiple NDCs as unavailable.
• 2024: Gradual improvement. Additional manufacturers bring capacity online. However, regional and dose-specific shortages persist.
• October 2025: The DEA increases the 2025 aggregate production quota (APQ) for d-amphetamine by approximately 25%, from 21.2 million grams to 26.5 million grams — a significant but overdue increase.
• January 2026: DEA publishes 2026 APQs that reflect higher production targets. Supply is improving but not yet normalized.

Prescribing implications

The shortage creates several challenges for prescribers:

Patients presenting with treatment gaps

Patients who have been unable to fill prescriptions may present with worsened ADHD symptoms, functional impairment, or anxiety about medication access. Some may have self-adjusted doses or borrowed medication. A non-judgmental approach to these conversations is important.

Increased prior authorization burden

When switching patients to alternative medications (e.g., from amphetamine/dextroamphetamine IR to lisdexamfetamine or methylphenidate), insurance plans may require prior authorization — adding administrative burden at a time when practices are already strained.

DEA prescribing rules remain strict

Schedule II prescriptions cannot include refills. Each fill requires a new prescription. Electronic prescribing of controlled substances (EPCS) is now required in most states, which has streamlined the process but still requires a new prescription for each 30-day supply.

Telehealth prescribing considerations

Following the DEA's post-pandemic rulemaking, telehealth prescribing of Schedule II stimulants has become more regulated. Confirm that your telehealth prescribing practices comply with current federal and state requirements, particularly regarding initial evaluations and in-person visit requirements.

Current availability picture

As of early 2026:

• Generic amphetamine/dextroamphetamine IR: Intermittently available. Availability varies significantly by dose strength (20 mg and 30 mg remain hardest to find), region, and pharmacy.
• Generic amphetamine/dextroamphetamine XR: Somewhat better availability than IR in many markets.
• Generic lisdexamfetamine (Vyvanse): Generally easier to find since generics launched in 2023. Consider as a first-line switch for patients who cannot access amphetamine/dextroamphetamine IR.
• Methylphenidate products: Less affected by the current shortage. Both IR and ER formulations are generally available.
• Dextroamphetamine (Zenzedi, generic): Variable availability; worth checking as an alternative single-entity amphetamine option.

40,370+ patients found their medications in stock

40K+

Find Amphetamine/Dextroamphetamine IR In Stock Today →

Cost and access considerations

Cost is a significant barrier for many patients, particularly the uninsured:

• Generic amphetamine/dextroamphetamine IR: $14 to $50 for a 30-day supply with discount coupons (GoodRx, SingleCare); approximately $30 to $55 at retail without coupons
• Generic lisdexamfetamine: $30 to $80 for a 30-day supply with coupons
• Generic methylphenidate IR: $15 to $30 with coupons

There are no active manufacturer savings programs for generic amphetamine/dextroamphetamine. Patient assistance through NeedyMeds and RxAssist may be available for qualifying patients. Directing patients to discount card programs can meaningfully reduce out-of-pocket costs.

Tools and resources for your practice

Medfinder for Providers offers tools that can help streamline the medication access process:

• Pharmacy availability search: Help patients identify pharmacies that currently stock their medication, reducing the "phone tag" burden on your office staff.
• Shortage monitoring: Stay informed about current supply status for amphetamine/dextroamphetamine IR and other commonly prescribed medications.

For detailed guidance on integrating these tools into your workflow, see our companion article: How to help your patients find amphetamine/dextroamphetamine IR in stock.

Additional resources

• FDA Drug Shortage Database: Official shortage listings and manufacturer updates
• ASHP Drug Shortage Resource Center: Clinical guidance during drug shortages
• DEA Diversion Control Division: Production quota information and prescribing regulations

Skip the calls, skip the stress.

Find Amphetamine/Dextroamphetamine IR In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Looking ahead

Several developments may improve the supply situation through 2026 and beyond:

• Increased DEA quotas: The 25% increase in d-amphetamine APQ should translate to more available product as manufacturers ramp up.
• New generic manufacturers: Additional companies have entered or are entering the generic amphetamine market, diversifying the supply chain.
• Expanded alternatives: The availability of generic lisdexamfetamine and newer ADHD medications provides more therapeutic options when specific formulations are unavailable.

However, the structural factors that created this shortage — strict DEA production controls, rising demand, concentrated manufacturing — will take time to fully resolve.

Final thoughts

The amphetamine/dextroamphetamine IR shortage has placed an extraordinary burden on patients and the clinicians who care for them. As prescribers, the most impactful actions you can take are:

1. Proactively discuss the shortage with patients before they run into problems
2. Have alternative medication plans ready for patients who cannot fill their prescriptions
3. Direct patients to tools like Medfinder that can help them locate available pharmacies
4. Advocate for policy changes — including more responsive DEA quota-setting — through professional organizations

For patient-facing resources you can share, see our articles on how to find amphetamine/dextroamphetamine IR in stock and alternatives to amphetamine/dextroamphetamine IR.